Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) – Pipeline Review, H2 2017’, provides in depth analysis on Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Central Nervous System and Metabolic Disorders under development targeting Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7)

The report reviews Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics and enlists all their major and minor projects

The report assesses Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Bionomics Ltd

Bristol-Myers Squibb Company

CoMentis Inc

Johnson & Johnson

Merck & Co Inc

NeuroDerm Ltd

Saniona AB

SK Biopharmaceuticals Co Ltd

Vanda Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Overview

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Companies Involved in Therapeutics Development

Bionomics Ltd

Bristol-Myers Squibb Company

CoMentis Inc

Johnson & Johnson

Merck & Co Inc

NeuroDerm Ltd

Saniona AB

SK Biopharmaceuticals Co Ltd

Vanda Pharmaceuticals Inc

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Drug Profiles

(nicotine + opipramol hydrochloride) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AN-761 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AQW-051 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AVL-3288 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AVL-8168 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-910731 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BNC-210 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BNC-375 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gln-1062 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GTS-21 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JNJ-39393406 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NBP-14 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SKLA-4R - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize Alpha-7 Nicotinic Acetylcholine Receptor for Alzheimer’s Disease and Schizophrenia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize CHRNA7 for Central Nervous System - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize NMDA Receptor and CHRNA7 for Central Nervous System - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Activate Neuronal Acetylcholine Receptor Subunit Alpha-7 for Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Dormant Products

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Discontinued Products

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Product Development Milestones

Featured News & Press Releases

Jun 15, 2017: Bionomics Invited to PTSD State of the Science Summit to Present Key BNC210 Data

May 18, 2017: Expanded BNC210 Clinical Data to be Presented at US Psychiatry Convention

Feb 03, 2017: Bionomics to Receive Milestone Payment from MSD for Initiation of Phase 1 Clinical Study of Candidate Alzheimer's Treatment

Jan 09, 2017: Bionomics Provides Update on BNC-210 Clinical Program At 2017 San Francisco Biotech Showcase

Sep 21, 2016: Bionomics Announces Positive Results from Phase 2 Trial of BNC210 in Generalized Anxiety Disorder

Sep 16, 2016: Bionomics to present anti-anxiety drug treatment trial results and ADHD treatment research at ECNP

Jun 30, 2016: Bionomics To Trial Drug Against Post-Traumatic Stress Disorder

Jun 24, 2016: Enrolment Completed in BNC210 Generalised Anxiety Disorder Trial

Mar 29, 2016: Neurodyn Cognition to Present Memogain Clinical Developments at Neurotech Investing and Partnering Conference

Dec 08, 2015: Post Traumatic Stress Disorder Identified as Major New Market Opportunity for BNC210

Sep 16, 2015: Bionomics Reports Positive Data from Phase 1 Multiple Ascending Dose Trial of BNC210 for Anxiety and Depression

Apr 20, 2015: Bionomics Initiates Phase II Clinical Trial Of BNC210 For Treatment Of Anxiety

Feb 02, 2015: Bionomics Begins Phase 1b Study With Anxiety Drug Bnc210

Nov 17, 2014: Bionomics to Present BNC210 at Society for Neuroscience Meeting

Nov 11, 2014: Bionomics to Progress BNC210 in Clinical Trials

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Indication, H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Investigation by Universities/Institutes, H2 2017

Products under Investigation by Universities/Institutes, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Pipeline by Bionomics Ltd, H2 2017

Pipeline by Bristol-Myers Squibb Company, H2 2017

Pipeline by CoMentis Inc, H2 2017

Pipeline by Johnson & Johnson, H2 2017

Pipeline by Merck & Co Inc, H2 2017

Pipeline by NeuroDerm Ltd, H2 2017

Pipeline by Saniona AB, H2 2017

Pipeline by SK Biopharmaceuticals Co Ltd, H2 2017

Pipeline by Vanda Pharmaceuticals Inc, H2 2017

Dormant Products, H2 2017

Dormant Products, H2 2017 (Contd..1), H2 2017

Dormant Products, H2 2017 (Contd..2), H2 2017

Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Top 10 Indications, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports